American College of Cardiology

MARCH 15, 2024

In this episode, the focus is on mitral valve disease. In these panel discussions, host Andrea Price MS, AACC brings together Bailey Estes MSN, AGNP-C, Nicole Dellise, NP, and Kristen deAlmeida, PharmD to explore best practices related to structural heart disease.

Bicuspid/Mitral 66

Bicuspid/Mitral Best Practices Heart Disease Article 66

American College of Cardiology

APRIL 16, 2024

Mitral annular calcification (MAC) is common in the setting of chronic kidney disease and aging. Previously presumed "degenerative" in etiology, cardiac/vascular calcification is now understood to be inflammatory, involving osteoblastic transformation of myofibroblasts.

Bicuspid/Mitral 58

Bicuspid/Mitral Kidney Disease Article 58

American College of Cardiology

JANUARY 4, 2024

What is the prevalence and what are the characteristics of mitral valve prolapse (MVP) in a large cohort of patients with unexplained cardiac arrest (UCA)?

Cardiac Arrest 62

Cardiac Arrest Bicuspid/Mitral Article 62

American College of Cardiology

MARCH 19, 2025

Two studies analyzing data from the STS/ACC TVT Registry exploring out-of-hospital 30-day mortality after mitral transcatheter edge-to-edge repair (TEER) and one-year cause-specific mortality after TAVR were published in JACC: Cardiovascular Interventions on March 19.

TAVR 54

TAVR Bicuspid/Mitral Cardiovascular Interventions Hospital 54

American College of Cardiology

AUGUST 31, 2024

The goal of the MATTERHORN trial was to evaluate mitral transcatheter edge-to-edge repair (M-TEER) compared with surgical mitral valve repair among patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 46

Bicuspid/Mitral Heart Failure Article 46

American College of Cardiology

OCTOBER 30, 2024

Several abstracts presented at TCT 2024, taking place Oct.

Chest Pain 56

Chest Pain Coronary Artery Disease TAVR Bicuspid/Mitral 56

American College of Cardiology

NOVEMBER 13, 2024

In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs. culprit-only revascularization in older patients with myocardial infarction (MI) with or without ST-segment elevation.

Bicuspid/Mitral 65

Bicuspid/Mitral Myocardial Infarction Hypertension Outcomes 65

American College of Cardiology

DECEMBER 16, 2024

Transcatheter edge-to-edge repair (TEER) and mitral valve (MV) surgery (both replacement and repair) are two approaches for managing patients with heart failure (HF) and secondary mitral regurgitation (MR).

Bicuspid/Mitral 43

Bicuspid/Mitral Heart Failure Article 43

American College of Cardiology

JANUARY 29, 2024

What are the long-term outcomes of mitral transcatheter edge-to-edge repair (M-TEER) compared to isolated mitral valve (MV) surgery among patients with severe mitral regurgitation (MR)?

Bicuspid/Mitral 49

Bicuspid/Mitral Outcomes Article 49

European Journal of Heart Failure

DECEMBER 11, 2024

Herein, we review the management of acute heart failure caused by VHD with a focus on transcatheter therapies and describe currently available evidence based on a systematic literature search on the following valve pathologies: (i) aortic stenosis, (ii) aortic regurgitation, (iii) mitral regurgitation, and (iv) mitral stenosis.

Cardiogenic Shock 68

Cardiogenic Shock Heart Disease Heart Failure Bicuspid/Mitral 68

American College of Cardiology

MARCH 22, 2024

What is the relationship between coarctation of the aorta (COA), bicuspid aortic valve (BAV), and thoracic aortic aneurysms?

Aneurysm 73

Aneurysm Aortic Aortic valve Bicuspid/Mitral 73

American College of Cardiology

MARCH 28, 2024

What is the performance of an artificial intelligence (AI)-derived risk score in predicting 1-year outcomes of patients with secondary mitral regurgitation (SMR) undergoing transcatheter edge-to-edge repair (TEER)?

Bicuspid/Mitral 52

Bicuspid/Mitral Outcomes Article 52

American College of Cardiology

OCTOBER 21, 2024

Patients with moderate or severe tricuspid regurgitation (TR) prior to undergoing TAVR or mitral transcatheter edge-to-edge repair (TEER), when compared to patients with no or mild TR, were associated with worse health status and clinical outcomes, according to a study published in JACC: Cardiovascular Interventions.

TAVR 49

TAVR Bicuspid/Mitral Outcomes Tricuspid 49

American College of Cardiology

AUGUST 31, 2024

The goal of the RESHAPE-HF2 trial was to assess the safety and efficacy of mitral transcatheter edge-to-edge repair (M-TEER) using MitraClip among symptomatic heart failure (HF) patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 46

Bicuspid/Mitral Heart Failure Article 46

American College of Cardiology

DECEMBER 10, 2024

The RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure: Second Trial in Patients With Clinically Significant Functional Mitral Regurgitation) trial was an international, open-label, multicenter, randomized controlled trial designed to provide additional information regarding the safety and effectiveness of M-TEER in this (..)

Bicuspid/Mitral 49

Bicuspid/Mitral Heart Failure Article 49

The British Journal of Cardiology

FEBRUARY 20, 2024

Patients with bicuspid aortic valves (BAV) are predisposed to the development of aortic stenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with BAV.

Aortic valve 40

Aortic valve Bicuspid/Mitral Aortic TAVR 40

Circulation

JANUARY 20, 2025

Circulation, Volume 151, Issue 3 , Page e27-e27, January 21, 2025.

Article 45

Article Heart Failure Bicuspid/Mitral Circulation 45

Circulation

JANUARY 20, 2025

Circulation, Volume 151, Issue 3 , Page e28-e28, January 21, 2025.

Article 45

Article Heart Failure Bicuspid/Mitral Circulation 45

American College of Cardiology

NOVEMBER 5, 2024

The goal of the COAPT trial was to assess the safety and efficacy of transcatheter mitral leaflet approximation using MitraClip among symptomatic heart failure (HF) patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 40

Bicuspid/Mitral Heart Failure Outcomes Article 40

European Journal of Heart Failure

APRIL 17, 2024

HFpEF, heart failure with preserved ejection fraction; MR, mitral valve regurgitation. Abstract Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF). The interplay of MR and HFpEF: understanding increased pulmonary pressures and strategies for management.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Bicuspid/Mitral Heart Failure Pulmonary 40

European Journal of Heart Failure

JANUARY 14, 2025

The International Registry of MitraClip in Acute Mitral Regurgitation following Acute Myocardial Infarction (IREMMI). Methods and results The International Registry of MitraClip in Acute Mitral Regurgitation following Acute Myocardial Infarction (IREMMI) includes 187 patients with severe MR post-MI managed with TEER.

Myocardial Infarction 40

Myocardial Infarction Bicuspid/Mitral Cardiogenic Shock Risk Factors 40

Circulation: Cardiovascular Interventions

JULY 29, 2024

Circulation: Cardiovascular Interventions, Ahead of Print.

Article 40

Article Cardiovascular Interventions Embolism Bicuspid/Mitral 40

American College of Cardiology

JUNE 18, 2024

Tremendous enthusiasm about mitral annulus disjunction (MAD) emerged in 2018 when Dejgaard et al. showed that, in their cohort of patients with mitral valve prolapse (MVP), MAD was associated with an increased risk of malignant ventricular arrhythmias (VAs).

Bicuspid/Mitral 62

Bicuspid/Mitral Arrhythmia Article 62

European Journal of Heart Failure

FEBRUARY 19, 2025

Prognostic impact of severe tricuspid regurgitation (TR) in patients with atrial functional mitral regurgitation (AFMR). Abstract Aims Tricuspid regurgitation (TR) is often seen in patients with atrial functional mitral regurgitation (AFMR).

Tricuspid 40

Tricuspid Bicuspid/Mitral Atrial Fibrillation Heart Failure 40

DAIC

MARCH 15, 2024

His research centers on the comprehensive management of patients post-TAVR, transcatheter mitral and tricuspid valve interventions, and advanced imaging techniques in structural heart disease. He has published over 250 peer-reviewed articles and lectures extensively worldwide.

TAVR 105

TAVR Academic Education Cardiovascular Surgery 105

American College of Cardiology

MARCH 29, 2024

In the past decade, the U.S. has seen a 25-fold increase in the use of TAVR, with more than 100,000 performed annually. This technique is now employed in approximately 85% of all isolated aortic valve replacements. Despite this growth, there are notable gaps in the evidence.

Bicuspid/Mitral 46

Bicuspid/Mitral Aortic Aortic valve TAVR 46

Journal of Cardiovascular Pharmacology

JULY 23, 2024

Despite its high prevalence, effective treatment for degenerative mitral regurgitation (MR) remains elusive. Despite its high prevalence, effective treatment for degenerative mitral regurgitation (MR) remains elusive.

Bicuspid/Mitral 40

Bicuspid/Mitral Cardiac Function Heart Failure Circulation 40

American College of Cardiology

NOVEMBER 6, 2024

The following are key points to remember from a state-of-the-art review on treatment options for patients with secondary mitral regurgitation (SMR).

Bicuspid/Mitral 61

Bicuspid/Mitral Article 61

American College of Cardiology

FEBRUARY 12, 2025

Electrosurgical leaflet laceration and stabilization of the implant (ELASTA-Clip) followed by transapical transcatheter mitral valve replacement (TMVR) is a feasible and less invasive option for management of failed mitral transcatheter edge-to-edge repair (M-TEER) that can be performed with acceptable results in a selected patient population.

Bicuspid/Mitral 49

Bicuspid/Mitral Article 49

Journal of Cardiovascular Electrophysiology

JANUARY 5, 2024

We investigated whether estimated perimitral conduction time (E-PMCT), namely, twice the time between coronary sinus (CS) pacing and the ensuing wave-front collision at the opposite side of the mitral annulus, correlated with the cycle length of PMAT and could predict future PMAT.

Bicuspid/Mitral 40

Bicuspid/Mitral Tachycardia Atrial Fibrillation Ablation 40

American College of Cardiology

APRIL 26, 2024

Transcatheter mitral valve-in-ring (MViR) using third-generation balloon-expandable aortic transcatheter heart valves was associated with a significant reduction in mitral regurgitation (MR) and improvement in heart failure symptoms at one year, with the tradeoff of elevated valvular gradients and a high rate of reintervention, according to a recent (..)

Bicuspid/Mitral 49

Bicuspid/Mitral Heart Valves Cardiovascular Interventions Heart Failure 49

American College of Cardiology

JANUARY 23, 2024

What are the outcomes of mitral valve transcatheter edge-to-edge repair (M-TEER) among patients with functional mitral regurgitation (FMR) who would have been excluded from the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) trial?

Bicuspid/Mitral 46

Bicuspid/Mitral Heart Failure Outcomes Article 46

American College of Cardiology

NOVEMBER 13, 2024

What are the outcomes of mitral transcatheter edge-to-edge repair (M-TEER) in patients with secondary mitral regurgitation (sMR) and preserved left ventricular ejection fraction (LVEF)?

Bicuspid/Mitral 43

Bicuspid/Mitral Outcomes Article 43

American College of Cardiology

JANUARY 17, 2024

He then discusses a recent comparison of direct oral anticoagulants vs Vitamin K antagonists after transcatheter mitral valve replacement. Eagle explores rethinking false positive exercise ECG Tests in patients with microvascular dysfunction.

Exercise 56

Exercise Bicuspid/Mitral Outcomes Article 56

American College of Cardiology

MARCH 29, 2024

My patient is 59 years old, has symptomatic severe aortic stenosis (AS) with a bicuspid aortic valve (BAV), and his proximal aorta is 3.6 cm in diameter. He has no important comorbidities and was referred for advice as to whether he should have a surgical (SAVR) or transcatheter (TAVR) aortic valve replacement. What should I counsel him?

Aortic valve 40

Aortic valve Bicuspid/Mitral TAVR Aortic 40

American College of Cardiology

JULY 29, 2024

What is the accuracy of three-dimensional (3D) transesophageal echocardiography (TEE) in predicting neo–left ventricular outflow tract (neo-LVOT) dimensions in patients undergoing transcatheter mitral valve replacement (TMVR), as compared with baseline computed tomography (CT)?

Bicuspid/Mitral 49

Bicuspid/Mitral Article 49

American College of Cardiology

MARCH 26, 2025

In this weeks View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock.

Cardiogenic Shock 40

Cardiogenic Shock TAVR Bicuspid/Mitral Article 40